Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.
New York, New York, United States Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. The fund has no exact preference in some founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low. Among the various public portfolio startups of the fund, we may underline Cala Health, Orasis Pharmaceuticals, Biolinq Among the most successful fund investment fields, there are Clinical Trials, Life Science.
We also calculated 3 valuable employees in our database.
Opposing the other organizations, this LifeSci Venture Partners works on 15 percentage points less the average amount of lead investments. The top amount of exits for fund were in 2019. The fund is generally included in 2-6 deals every year. The common things for fund are deals in the range of 10 - 50 millions dollars. Considering the real fund results, this VC is 6 percentage points less often commits exit comparing to other organizations. The important activity for fund was in 2019.
The standard case for the fund is to invest in rounds with 6-7 partakers. Despite the LifeSci Venture Partners, startups are often financed by Roche Venture Fund, RiverVest, Novo Ventures. The meaningful sponsors for the fund in investment in the same round are Rock Springs Capital, Redmile Group, Boxer Capital. In the next rounds fund is usually obtained by JDRF T1D Fund, Aphelion Capital.
Related Funds
Funds with similar focus
| Fund Name | Location |
| 10x | England, London, United Kingdom |
| Amplifi | India, Maharashtra, Mumbai |
| Barium Capital | Kenya, Nairobi, Nairobi Area |
| Brighton Health Group | California, Spring Valley, United States |
| BTC Investment | - |
| Carao Ventures | Costa Rica, San José, San Jose Province |
| IDB Lab | District of Columbia, United States, Washington |
| Limestone Fund | Estonia, Harjumaa, Tallinn |
| Lundbeckfonden Emerge | Copenhagen, Denmark, Hovedstaden |
| MicroAd | Japan, Tokyo |
| Mitsubishi Hitachi Power Systems | Japan, Kanagawa Prefecture, Yokohama |
| National Bank of Canada | NAventures | - |
| Pocket Ventures | Boulder, Colorado, United States |
| RIDE MEDIA & DESIGN | Hokkaido Prefecture, Japan, Meguro |
| Third Point Ventures | New York, New York, United States |
| Vision Plus Capital | China, Hangzhou, Zhejiang |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
MOMA Therapeutics | $150M | 10 May 2022 | Cambridge, Massachusetts, United States | ||
Beta Bionics | $57M | 17 Feb 2022 | Boston, Massachusetts, United States | ||
Silagene | $75M | 19 Jan 2022 | New Jersey, United States | ||
Antios Therapeutics | $75M | 03 Nov 2021 | Atlanta, Georgia, United States | ||
Antios Therapeutics | $96M | 12 Apr 2021 | Atlanta, Georgia, United States | ||
Pyxis Oncology | $152M | 30 Mar 2021 | Boston, Massachusetts, United States | ||
Iridia | $24M | 16 Mar 2021 | Carlsbad, California, United States | ||
Caribou Biosciences | $115M | 03 Mar 2021 | Berkeley, California, United States | ||
EGenesis | $125M | 02 Mar 2021 | Cambridge, Massachusetts, United States |
– RayzeBio, Inc. announced a $108m Series C financing led by Venrock Healthcare Capital Partners alongside new investors Perceptive Advisors, Vivo Capital, Acuta Capital Partners, Deerfield Management, and TCG X.
– Also participating were all of Rayze’s existing investors: venBio Partners, Versant Ventures, Samsara BioCapital, Redmile Group, Viking Global Investors, Cormorant Asset Management, OrbiMed, LifeSci Venture Partners, Logos Capital, Alexandria Venture Investments, and others.
– The targeted radiopharmaceuticals field represents a highly clinically validated modality that, until recently, has been underappreciated.
– With over $258m of capital raised since the company first debuted in the second half of 2020, RayzeBio has rapidly expanded its team, infrastructure, capabilities, and pipeline.
– Antios Therapeutics from San Diego, CA announced the successful completion of a $96m Series B financing.
– The financing was led by Soleus Capital with participation from new major investors RA Capital Management, Adage Capital Management LP, Pontifax and Aisling Capital as well as other healthcare focused funds, Altium Capital, Amzak Health, Granite Point Capital Management, LP, and LifeSci Venture Partners and participation from all of the original Series A investors including Lumira Ventures, CAM Capital, Delos Capital, Domain Associates and Sixty Degree Capital.
– Antios Therapeutics is a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data 
Get matched with relevant funds
